Akorn confirms discussions to be potentially acquired

LAKE FOREST, Ill. — Specialty generic pharmaceutical company Akorn confirmed it is in talks to be possibly be acquired by Fresenius Kabi, a subsidiary of Fresenius SE & Co. KGaA.

Entry into a formal agreement with respect to a transaction remains subject to, among other things, approval by the Executive Board and Supervisory Board of Fresenius Management SE and the board of directors of Akorn. There can be no assurance any transaction will result from these discussions, or as to the terms of any such transaction, stated Akron

Neither Fresenius SE & Co. KGaA nor Akorn intend to make any additional comments regarding these negotiations unless and until it is appropriate to do so, or a formal agreement has been reached.

Lake Forest-based Akorn is engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals.